Bioventus Inc. is a medical device company. The Company is focused on developing and commercializing clinically differentiated and minimally invasive treatments that engage and enhance the bodyâs natural healing process. Its portfolio of products is grouped into three areas. Its Pain Treatments include non-surgical pain injection therapies as well as peripheral nerve stimulation (PNS) products to help the patient get back to their normal activities. Its Surgical Solutions include bone graft substitutes (BGS) that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries, as well as a portfolio of ultrasonic products used for precise bone cutting and sculpting, soft tissue management and tissue debridement in various surgeries. Its Restorative Therapies comprise a bone stimulation system, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis or other central nervous system disorders.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļBVS
āļāļ·āđāļāļāļĢāļīāļĐāļąāļBioventus Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļFeb 11, 2021
āļāļĩāļāļĩāđāļMr. Robert E. Claypoole
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ930
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļFeb 11
āļāļĩāđāļāļĒāļđāđ4721 Emperor Boulevard, Suite 100
āđāļĄāļ·āļāļDURHAM
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ Global Select Consolidated
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ27703
āđāļāļĢāļĻāļąāļāļāđ19194746700
āđāļ§āđāļāđāļāļāđhttps://www.bioventus.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļBVS
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļFeb 11, 2021
āļāļĩāļāļĩāđāļMr. Robert E. Claypoole
Mr. Anthony D'adamio, J.D.
Mr. Anthony D'adamio, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
Ms. Susan M. Stalnecker
Independent Director
Mr. Guy Paul Nohra
Independent Director
Mr. Guido J. Neels
Independent Director
Mr. John A. Bartholdson
Independent Director
Mr. Patrick J. (Pat) Beyer
Mr. Patrick J. (Pat) Beyer
Independent Director
Ms. Michelle Mcmurry-Heath, M.D., Ph.D.
Ms. Michelle Mcmurry-Heath, M.D., Ph.D.
Independent Director
Mr. Philip G. Cowdy
Independent Director
Mr. Mark Singleton
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
Ms. Katrina Church, J.D.
Senior Vice President, Chief Compliance Officer
Senior Vice President, Chief Compliance Officer
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Anthony D'adamio, J.D.
Mr. Anthony D'adamio, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
Ms. Susan M. Stalnecker
Independent Director
Mr. Guy Paul Nohra
Independent Director
Mr. Guido J. Neels
Independent Director
Mr. John A. Bartholdson
Independent Director
Mr. Patrick J. (Pat) Beyer
Mr. Patrick J. (Pat) Beyer
Independent Director
Harbor Human Capital Factor US Small Cap ETF
Lattice Hartford Multifactor Small Cap ETF
VictoryShares Small Cap Free Cash Flow ETF
Vanguard US Multifactor ETF
Fidelity Enhanced Small Cap ETF
Avantis US Small Cap Value ETF
WisdomTree US SmallCap Fund
Avantis US Small Cap Equity ETF
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Harbor Human Capital Factor US Small Cap ETF
āļŠāļąāļāļŠāđāļ§āļ0.17%
Lattice Hartford Multifactor Small Cap ETF
āļŠāļąāļāļŠāđāļ§āļ0.12%
VictoryShares Small Cap Free Cash Flow ETF
āļŠāļąāļāļŠāđāļ§āļ0.09%
Vanguard US Multifactor ETF
āļŠāļąāļāļŠāđāļ§āļ0.08%
Fidelity Enhanced Small Cap ETF
āļŠāļąāļāļŠāđāļ§āļ0.08%
iShares Micro-Cap ETF
āļŠāļąāļāļŠāđāļ§āļ0.07%
Avantis US Small Cap Value ETF
āļŠāļąāļāļŠāđāļ§āļ0.04%
Humankind US Stock ETF
āļŠāļąāļāļŠāđāļ§āļ0.03%
WisdomTree US SmallCap Fund
āļŠāļąāļāļŠāđāļ§āļ0.03%
Avantis US Small Cap Equity ETF
āļŠāļąāļāļŠāđāļ§āļ0.03%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē

āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ